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The Curious Case of Cuba's Biotech Revolution 
Helen Yaffe, University of Glasgow   
 
In late September 2018, the first US-Cuban biotech joint venture was established to trial CIMAVax-
EFG, an innovative Cuban lung cancer immunotherapy treatment, with the intention of delivering it 
to patients in the United States. Innovative Immunotherapy Alliance SA was set up by Buffalo-based 
Roswell Park Comprehensive Cancer Center and Havana’s Centre for Molecular Immunology (CIM); 
two institutions which benefited from the tentative rapprochement between the US and Cuba in mid-
December 2014. The sheer fact that such an entity should exist is scientifically and politically ground-
breaking for several reasons: First, it testifies to the extraordinary development of biotechnology in 
Cuba, a case largely overlooked in medical science and business history literature on the field.1 
Havana’s Scientific Pole, a complex in Western Havana which hosts over 50 major integrated 
research, education, health, and commercial biotech institutions, is not included in references to 20 
global biotech regions.2 Lara Marks’ masterful 2015 history of the development of monoclonal 
antibodies (MABs) omits Cuban advances that have placed the island at the forefront of MAB-based 
immunology therapies.3  
 
Second, despite the fact that for nearly 60 years the United States blockade has obstructed Cuba’s 
foreign trade, external financing, technology transfers and scientific exchange, including in the 
medical field, it is the Cubans who have contributed the innovative science to this joint venture; they 
have cracked a difficult nut - using immunology therapy to combat cancer. Third, while global 
biopharma is associated with speculative, mostly private, capital, the Cuban industry is entirely state-
owned and financed. The emergence of the Scientific Pole for example, was the result of state 
planning, not market forces attracting private interests to a given location. Cárdenas points out that 
‘the State is focused not only on fast returns, but also on long term socioeconomic targets’.4 
 
Finally, Cuban ‘exceptionalism’ does not lie in the mere fact of government support and/or public 
funding for the biotech industry; several analysts have pointed to this feature in the United States 
and elsewhere. The exceptionalism lies in the political economy context; Cuba is a small island nation 
that can boast ‘developed-country health outcomes despite its developing-country economy’.5 
Arguably this has been possible because it has a centrally-planned, state-controlled economy, and a 
development strategy which has prioritised healthcare, education, and research into science and 
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technology from the early 1960s. The universalisation of (free) education, beginning with the Literacy 
Campaign of 1961 and the University Reform of 1962, generated a ‘critical mass’ of scientists, many 
of whom initially were sent abroad to study. The Revolution also committed to provide free public 
health and pursued a policy of ‘medical internationalism’ from the outset. But the global 
pharmaceutical industry is dominated by the United States, the country imposing the comprehensive 
blockade of the island. Thus, the development of a domestic capacity to produce medical drugs and 
supplies was an imperative forced on Cuba, particularly after the loss of Cuba’s socialist trade 
partners around 1990. Beyond the political economy framework, also important is the historical 
context of Cuban medical science, with its focus on parasitology and immunotherapy and the fact 
that the biotech sector was initiated with researchers came from biophysics and nuclear physics.6  
While Cuban scientists claim that their biotech revolution, ‘demonstrates the feasibility of developing 
a new industry in a developing country under foreign economic pressures’, the specific historical and 
political context within which the sector developed mean that the Cuban case is difficult to emulate.7   
 
Biotechnology is the application of biological knowledge and techniques pertaining to molecular, 
cellular, and genetic processes to develop products and services.8 Biological research into genomes 
and cells does not constitute biotechnology unless it involves industrial production. In that sense, 
Biotechnology is a manufacturing process, but the transformation of the raw material into a final 
product is done inside a living cell.9 The world’s first biotechnology enterprise was established in the 
United States in 1976. Just five years later, in 1981, the Biological Front was set up to develop the 
industry in Cuba. This was the first time in its economic history that Cuba had incorporated itself into 
an emerging industrial sector. While most developing countries had little access to the new 
technologies (recombinant DNA, human gene therapy, biosafety), Cuban biotechnology expanded 
and took on an increasingly strategic role in both the public health sector and the national economic 
development plan.10 It did so despite the US blockade obstructing access to technologies, equipment, 
materials, and even knowledge exchange.  
 
Among Cuba’s biotech innovations are the world’s first Meningitis B vaccine, treatment for diabetic 
foot ulcers, vaccines for Hepatitis B and dengue, and the world’s first human vaccine with a synthetic 
antigen (a vaccine against Haemophilus influenza type b, or Hib).11 Today, Cuba is among world 
leaders in oncology drugs. In 2012, CIM patented the first therapeutic lung cancer vaccine. In 
examining the curious case of Cuba’s biotech revolution, this article starts with an overview of the 
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industry in the advanced capitalist countries, particularly the United States, to better appreciate what 
makes the Cuban case so distinctive.  
 
The rise of the biotechnology sector 
California hosted the first and the largest biotech companies: Genetech was founded in San Francisco 
in 1976 by venture capitalist Robert A. Swanson and biochemist Herbert Boyer; and AMGen was set 
up in Los Angeles in 1980. Boston and San Francisco were leading biotech hubs early on and continue 
to be dominant. The location was no coincidence. These cities each have three of the nation’s 20 top-
ranked medical research institutions.12 Biotech firms set up in close proximity to medical science 
research institutions (universities, hospitals, research centres) hosting the best scientists and 
facilities, ‘and a globalising market where the best and the brightest from all over the world come to 
study’13. Those institutions receive government funding that runs into the billions of dollars annually. 
Studies have also shown the importance of access to local venture capital as a determinant of biotech 
firm location.14  
 
In the early 20th century the US pharmaceutical industry developed in clusters between New York 
and Philadelphia, and these regions went on to develop substantial concentrations of biotech activity 
in the late 20th century.15 San Diego, Seattle and Raleigh-Durham subsequently emerged as hubs. By 
2002, these three cities had received ‘an average of $500 million annually in National Institutes of 
Health (NIH) funding (in 2001 dollars) for more than a decade and $750 million new venture capital 
investment during the past six years, and each area also has one or more of the nation’s 20 top ranked 
medical research universities’.16 By the outset of the 21st century, the US biotech sector was 
concentrated in 9 of the country’s 51 largest metropolitan areas.  
 
Biotechnology took off in Europe in the 1990s, and subsequently in Japan, Singapore and China. By 
2009, there were more biotech firms in Europe than in the US.17 The character of the industries 
differed in that the US had twice as many publicly listed companies than Europe and more access to 
venture financing than the European industry. In 2008, three decades after the industry began, there 
were 1,754 biotech firms in the US, 371 of them publicly listed, and sector employment was hovering 
below 200,000.18 But ‘progress’ was often evasive. Most small biotech firms were losing money. Half 
of US biotech firms formed since the 1970s had folded or were merged into other companies by 
2000.19 Internationally, the biotech sector did not achieve profits from product sales until 2009.  
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Nonetheless, billions of dollars poured into the industry. Lazonick and Tulum refer to this as the 
‘Pisano Puzzle’, after Harvard Professor Gary Pisano’s 2006 book questioned why money from 
venture capital and big pharma flowed into an industry in which profits are so hard to come by.20 The 
answer is the role of financial mechanisms such as Initial Public Offerings (IPOs), Special Purpose 
Entities (SPEs), Special Purpose Corporations (SPCs), and patents licenses, in permitting profits to be 
made from a high-tech sector with low productivity. Start-up firms typically depend on venture 
capital investment to underwrite their initial costs. Cortright and Mayer explain that once some 
promising products are developed, venture capitalists and other early-stage investors seek to recoup 
their investment (or a portion of it) by having the firm issue stock to the public in an ‘initial public 
offering’ (IPO).21 However, biotechnology products can take up to 20 years to commercialise, and 
many will never reach that point. By 2002, only about 100 biotech-related drugs had reached the 
market in 30 years, with the top ten accounting for nearly all of the sales.22 In 2011, Lazonick and 
Tulum pointed out that virtually all biopharma companies that do IPOs are product-less: ‘Rather than 
waiting 10-20 years to see whether a commercial drug will in fact be produced, the existence of a 
speculative stock market provides [venture capital and big pharma] with a mode of exit from their 
investments by mean of an IPO’.23 Without such mechanisms, capital may never have been made 
available.  
 
The 1971 establishment of the NASDAQ stock exchange, for financing risk-intrinsic high-tech 
businesses, and the rising power of financial capital since the early 1980s, shaped the emerging 
biotechnology sector. ‘The stock exchange has become an instrument for subordinating corporations 
to the management norms and profitability standards requested by the shareholders…the evolution 
of the biotechnology industry clearly illustrates these findings’, concludes Christian Zeller.24 However, 
this relationship hides the vital role of US government policy in almost every stage of the biotech 
industry.  
 
Public money for private profit?  
Cortright and Mayer list the forms this take: the government heavily subsidises the training of medical 
researchers; US patent policy is set by Congress and administered by the US Patent and Trademark 
Office; the Food and Drug Agency (FDA) has to approve most biotech products and regulates 
conditions for manufacturing and advertising to consumers; decisions on healthcare and what drugs 
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or therapies to include on national health care programmes like Medicare and Medicaid are 
decisive.25 Lazonick and Tulum conclude: ‘The biopharmaceutical industry has become big business 
because of big government [and] remains highly dependent on big government to sustain its 
commercial success.’26  
 
The US government funds basic science through National Institutes of Health. Between 1978 and 
2004, NIH spending on life sciences totalled $365 billion in 2004 dollars.27 US institutions provide 
legislative support for the private biotech sector; the 1980 Bayh-Dolye Act gave universities and 
hospitals clear property rights to new knowledge that resulted from federally-funded research. Also 
in 1980, the Supreme Court decision in Diamond vs. Chakrabarty ruled that genetically engineered 
life forms are patentable. The Orphan Drug Act of 1983 provided generous tax credits for 
pharmaceutical companies that develop drugs for rare diseases. By 2008, orphan drugs accounted 
for 74% of total revenues and 75% of product revenues of the six leading companies.28 
 
Lazonick and Tulum argue that these financial mechanisms and the wide scope of IP protection in 
biotechnology has become an obstacle to follow-on innovation, by limiting the new entrants who 
would compete to produce better and cheaper drugs, while financial speculation permits stock-
market investors to reap huge rewards by trading biopharma stock, even in the absence of a 
commercial product. A similar view is strongly held by the Cuban medical scientists. Certainly, the 
absence of such financial mechanisms has contributed towards the distinctive character of their 
biotechnology industry. However, biopharma developments on the island also build upon a long 
history of infectious disease vaccinations. And that story begins in the nineteenth century. 
 
The historical trajectory of Cuban medical science  
Three private science institutes were set up in 19th century Cuba,29 but the best known medical 
scientist of the century is Carlos Finlay who was born in colonial Cuba in 1833 to a Scottish father and 
a French mother. In 1881, Finlay presented a ground-breaking theory that the transmission vector, 
or carrier, of yellow fever was the mosquito. The following year, Finlay identified the Aedas aegypti 
mosquito as the culprit, and recommended controls to halt the spread of the disease. His finding was 
described as the greatest advance in medical science since the discovery of the smallpox vaccine in 
1796.30 Following Cuba’s formal independence, between 1902 and 1909, Finlay served as Cuba’s chief 
health officer.31  
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There were other outstanding individuals in the decades that followed, but the period between 
Cuban ‘independence’ in 1902 and the Revolution of 1959 were austere years for medical science. 
The country had only three universities; in Havana, Oriente (Santiago) and Villa Clara (set up in 1952), 
and they conducted little medical research. In 1937, Dr Pedro Kouri privately founded the Institute 
of Tropical Medicine, which did conduct investigations and earned a good international reputation 
among parasitologists and other specialists of Tropical Medicine.  
 
Private medical clinics thrived, largely by offering US clients’ services at lower cost than home, or 
services not available in the US.32 There was a tradition of eminence in surgery. The big money 
spinner was cosmetic surgery which generated $5 million a year between 1948 and 1958. The main 
causes of childhood death on the island were parasitic infestation, gross malnutrition and enteric 
infections, leading to diarrhoea and dehydration. But the paediatrics department at the University of 
Havana Medical School barely addressed these ailments. Instead it specialised in hyperactivity and 
leukaemia.  
 
There was also a medical focus on the diagnosis and treatment of cancer. Created in 1925, the League 
against Cancer in Cuba secured private funding to set up the hospital ‘Calixto Garcia’ where 
prestigious Cuban medics held private clinics. In 1929, the Institute of Cancer was set up, the first to 
treat malignant growths. Subsequently two more oncology centres were founded, mainly to treat 
patients in the advanced stages of cancer. Most of the doctors did not receive payment; this was 
philanthropic work. They did teach, however, and exchanged scientific information and experiences 
with oncology centres in developed countries.  
 
The 1950 report by the Truslow Commission of the International Bank of Reconstruction and 
Development declared that ‘the Mission could not find any suitable applied research laboratory, 
public or private, in Cuba’.33 Three years later, the 1953 census recorded that 60% the population 
had between three years and no education.34 Just over 1% of Cubans had university education, and 
of those only 1.7% were science students who mostly graduated without practical experience.  
 
Revolutionary change from 1959  
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Speaking at the Cuban Academy of Sciences in mid-January 1960, one year after the Rebel Army took 
power, Fidel Castro declared: ‘The future of Cuba will be a future of men of science.’ This must have 
seemed like a pipe dream, given the backward state of Cuban scientific research and generally low 
level of education. The Revolution, declared Castro, was sowing opportunities for intelligence. It 
needed thinking men who would put their intelligence to ‘good’, on the side of ‘justice’, in the 
interests of the nation.  
 
Initiated the following January, the literacy campaign of 1961 reduced illiteracy from 24% to 4% in 
Cubans over-ten years old within one year. It was followed by the University Reform Law in January 
1962, which removed their traditional autonomy and, by eliminating fees and facilitating access at all 
levels, opened the universities to the children of workers, peasants and non-white Cubans. Courses 
were introduced to train the specialists required for the Revolution’s economic development plans. 
In 1962 the Cuban government created the National Commission for the Academy of Sciences of 
Cuba. New schools, colleges and universities were built, new teachers trained. Thousands of Cuban 
students studied in the socialist bloc countries, while others received scholarships from the west. 
Free, universal public healthcare provision was introduced.35 From 1962 a national immunisation 
programme provided all Cubans with eight vaccinations free of charge. Infectious diseases were 
rapidly reduced, then eliminated, including polio (eliminated 1962); malaria (1968); diphtheria 
(1971); measles (1993); pertussis (1994); and rubella (1995).36  
 
Guevara: revolutionary, medic, industrialist  
In 1959, Cuba was dependent on US pharma for medicines. The market was dominated by two firms 
which made exorbitant profits. The industry was expropriated by revolutionary decree, putting 
production and distribution of medicines into government hands. It fell under the jurisdiction of 
Ernesto ‘Che’ Guevara as Minister of Industries. In his pre-revolutionary life, Guevara had graduated 
as a medic and researched allergies, asthma, leprosy and nutritive theory. As Minister, he set up nine 
research and development institutes, including, in 1963, the Institute for the Development of the 
Chemical Industry to foster the industrial application of human and animal anti-biotics.37 While 
progress was limited, the institute established a research methodology which later became a 
distinctive feature of Cuban biotechnology. ‘The idea was excellent’, claims Tirso Saenz, then 
Guevara’s Vice Minister of Science and Technology, ‘to make an institution with what they call a 
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complete cycle of innovation. The institute develops products at a scale where it can build pilot plants 
which, if successful, are turned into production plants.’38  
 
Guevara commandeered an abandoned farm, to use for socio-productive and botanical 
experiments.39 The personnel were students from the Rebel Army School, and they were joined by 
Chinese medical scientists, a Cuban post-doctoral researcher and three agronomy engineers. From 
the farm two dozen varieties of medicinal plants were supplied to scientists conducting laboratory 
experiments in the Hospital of Oncology in Havana. The fourth floor of the Hospital had 40 scientists 
working under Guevara’s directives on laboratory experiments with plants, animals and raw 
materials.40  
 
Guevara left Cuba in 1965 and the farm was transferred to the newly established National Centre for 
Scientific Research (CENIC), set up to initiate biological studies and a new scientific infrastructure. 
The directors in the post-1980 biotechnology institutes all began as students in CENIC.41 Throughout 
the 1960s and 1970s, thousands of Cubans trained as scientists and engineers. Cuba achieved 1.8 
researchers per 1,000 inhabitants, well above the Latin America mean (0.4) and close to that of 
Europe (2.0).42 Among the many institutions created was the National Council of Science and 
Technology, in 1975, the same year that a new national scientific policy was approved at the First 
Congress of the Cuban Communist Party.   
 
By the 1980s Cuba had the health profile of a highly developed country, having eliminated most 
infectious and poverty-related diseases, so that ailments like cancer, diabetes and heart disease 
became priorities, on a par with the developed capitalist world. These conditions are expensive to 
treat. Additionally, a new law passed by US President Reagan in 1982 prohibited foreign nations from 
exporting goods and equipment to Cuba if any part or process in its manufacture had been mediated 
by US companies or individuals. Cuban subscriptions to US science and technology journals could not 
be honoured.43  
 
The curious origins of Cuban biotechnology 
Cuba’s biotechnology sector emerged independently from both the Soviet Union and the corporate 
capitalist model in the US and Europe.44 Driven by public health demand, it has been characterised 
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by the fast track from research and innovation to trials and application. This is illustrated by the story 
of how interferon was used to arrest a deadly outbreak of the dengue virus in 1981.45  
 
Interferons are ‘signalling’ proteins produced and released by cells in response to infections (viruses, 
bacteria, parasites and tumour cells) which alert nearby cells to heighten their anti-viral defences. 
They were first identified in 1957 by Jean Lindenmann and Aleck Isaacs at the National Institute of 
Medical Research in London during their research into ‘viral interference’ - the process by which a 
cell that is infected by one virus can produce an immune response which protects it from another 
virus. Following this breakthrough, in the 1960s Ion Gresser, a US-researcher in Paris, showed that 
interferons stimulate lymphocytes that attack tumours in mice.  
 
In 1970s, US oncologist Randolph Clark Lee, Director of a Cancer Hospital in Houston, Texas, took up 
this research. Catching the tail end of US President Carter’s improved relations with Cuba, Clark 
joined a delegation to visit the island’s health facilities. During the trip Clark met with Fidel Castro 
and convinced him that interferon was the wonder drug. Clark offered to host a Cuban researcher at 
his hospital. Castro persuaded him to take two. Shortly afterwards, a Cuban doctor and a 
haematologist spent time in Clark’s laboratory. He gave them the latest research about interferon 
and put them in contact with Kari Cantell, the researcher who, in the 1970s, had isolated interferon 
from human cells. Cantell’s commitment to global health led him to share his breakthrough without 
patenting his interferon procedure. In March 1981, six Cubans spent 12 days in Finland learning to 
produce large quantities of interferon. They were from the first generation of medical scientists 
entirely trained under the Revolution of 1959. 
 
In April 1981, the day after returning from Finland, the Cubans moved into ‘House 149’, a former 
mansion converted into an interferon laboratory, which became the Centre for Biological Studies. 
Fidel Castro visited them frequently, securing them the resources they required. Within just 45 days 
the Cubans had produced their first Cuban batch of interferon. Safety and sterility tests were 
performed on mice before three of the scientists inoculated themselves. They experienced a slight 
rise in temperature, nothing worse. The laboratory in Finland confirmed the quality of their 
interferon.  
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Just in time, it turned out. Weeks later Cuba was struck by an epidemic of dengue, another disease 
transmitted by mosquitos. Notably, it was the first time this particularly virulent strand, which can 
trigger life-threatening dengue haemorrhagic fever, had appeared in the Americas. The epidemic 
affected 340,000 Cubans with 11,000 new cases diagnosed every day at its peak.46 180 people died, 
including 101 children. The Cubans suspected the CIA of releasing the virus. Castro announced: ‘We 
share the people’s convictions and strongly suspect that the plagues that have been punishing our 
country, especially the hemorrhagic [sic] dengue, could have been introduced into Cuba, into our 
country, by the CIA’.47 The US State Department flatly denied it, although a recent Cuban 
investigation claims to provide evidence that the epidemic was introduced from the US.48  
 
At the height of the epidemic, Cuba’s Ministry of Public Health (MINSAP) authorised the scientists in 
House 149 to use interferon to halt it. This was done at great speed. They found that in advanced 
cases of dengue, interferon was not useful, but in recent infections in children, it cut short cases of 
haemorrhagic dengue shock. Mortality declined. In their historical account, Cuban scientists 
Caballero Torres and Lopez Matilla claim: ‘It was the most extensive prevention and therapy event 
with interferon carried out in the world. Cuba began to hold regular symposia, which quickly drew 
international attention’.49 The first international event in 1983 was prestigious; Cantell gave the 
keynote speech and Clark attended with Albert Bruce Sabin, the Polish American scientist who 
developed the oral polio vaccine that has helped to nearly eradicate the disease globally.  
 
Convinced about the contribution and strategic importance of innovative medical science, the Cuban 
government set up the ‘Biological Front’ to develop the sector. In January 1982, the Centre for 
Biological Studies moved from House 149 into a newly built and better-equipped laboratory, with 80 
researchers. Cuban scientists went abroad to study, many in western countries. Their research took 
on more innovative paths, as they experimented with cloning interferon. By the time Cantell returned 
to Cuba in 1986, the Cubans had developed a second generation interferon cloned in yeast.50  
 
In 1982, the United Nations Industrial Development Organisation (UNIDO) launched a competition 
for an internationally-funded project to foster biotechnology in the ‘Third World’. UNIDO’s 
International Centre for Genetic Engineering and Biotechnology was to facilitate North-South 
knowledge transfer and cooperation in science. Reagan’s 1982 measures tightening the US blockade 
gave Cuba an additional incentive to apply. In 1984, the fund was awarded to a joint application by 
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India and Italy. However, the Cubans, and most emphatically Fidel Castro, decided to proceed 
without support. Construction immediately began on Cuba’s showpiece Centre for Genetic 
Engineering and Biotechnology (CIGB), to work in biology, chemical engineering and physics. It 
opened just two years later in 1986. By then Cuba was submerged in another health crisis, a serious 
outbreak of Meningitis B, which further spurred Cuba’s biotechnology sector.  
 
Cuba’s Meningitis Miracle  
In 1976, Cuba was struck by meningitis B and C outbreaks.51 Since 1916 only a few isolated cases had 
been seen on the island. At that point, internationally, vaccines existed for Meningitis A and C, but 
not for B. Cuban health authorities secured a vaccine from a French pharmaceutical company to 
immunise the population against type C Meningitis. However, in the following years, cases of type B 
Meningitis began to rise. With infections and fatalities on the increase, in 1983 MINSAP established 
a team of specialists from different medical science centres, led by a woman biochemist, Concepción 
Campa, to work intensively on finding a vaccine. By 1984 Meningitis B had become the main health 
problem in Cuba. After six years of working around the clock, in 1988, Campa’s team produced the 
world’s first successful Meningitis B vaccine. Again, the scientists tested the vaccine on themselves, 
and their own children, before beginning clinical trials. Between 1987 and 1989, a randomised, 
double-blind controlled trial of the vaccine efficacy took place, with over 100,000 students aged 10 
to 14 years. The results showed the vaccine to be 83% effective. Another member of Campa’s team, 
Dr Gustavo Sierra recalled their joy: ‘this was the moment when we could say it works, and it works 
in the worst conditions, under pressure of an epidemic and among people of the most vulnerable 
age.’52 
 
MINSAP decided that more lives would be saved by starting nationwide vaccinations immediately 
with an 83% effective vaccine than delaying until a more effective one was produced (or not). During 
1989 and 1990, three million Cubans, those most at risk (children and young people), were 
vaccinated. In the roll out, the efficacy ranged from 83% to 94% in difference provinces. No severe 
reactions occurred and another severe disease outbreak had been halted. Subsequently, 250,000 
young people were vaccinated with the VA-MENGOC-BC vaccine, a combined Meningitis B and C 
vaccination. It recorded 95% efficacy overall, with 97% in the high-risk three months to six years age 
group. Cuba’s Meningitis B vaccine was awarded a UN Gold Medal for global innovation. This was 
Cuba’s meningitis miracle.53  
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‘I tell colleagues that one can work 30 years, 14 hours a day just to enjoy that graph for 10 minutes,’ 
says Agustin Lage, Director of the Centro for Molecular Immunology (CIM), referring to an illustration 
of the rise and sudden fall of Meningitis B cases in Cuba. ‘Biotechnology started for that. But then the 
possibilities of developing an export industry opened up, and today, Cuban biotechnology exports to 
50 countries.’54 This possibility came about after an outbreak of Meningitis B in Brazil a few years 
later. ‘The Brazilians bought the Cuban vaccine. It was a huge purchase and that money was invested 
in expanding the biotechnology industry here’, says Lage.  
 
By 1986, Cuba had 39,000 scientific workers; one for every 282 people. 23,000 were involved in 
research. Thousands had been trained abroad, mainly in the socialist countries, but also in Western 
Europe. The revolutionary government’s investments in education and public health had created the 
‘critical mass’ necessary for further progress in medical science. The Biological Front invested $1 
billion to develop a biotechnology industry between 1981 and 1989, including establishing the 
Western Havana Scientific Pole, known as Science City, between 1986 and 1991.55  
 
Science City  
Science City is a cluster of biotechnology institutions that co-ordinate and integrate their work. 
Centre directors met monthly to discuss projects and exchange information in meetings attended by 
top government officials, including Fidel Castro. Thousands of housing units were constructed locally 
to enable the institution’s employees, working daily shifts of 14 hours, to walk to work. At the centre 
of Science City is the CIGB, which received the greatest investment in a Cuban science institution. 
Other institutions followed:  
 1987, the Centre for Immunoassay: to manufacture computerised and automated equipment for 
biochemical tests and screenings to detect pathologies.  
 1989, the National Centre for Meningococcal Vaccines: for research and production of the VA-
MENGOC-BC vaccine and other human vaccines. It was renamed the Finlay Institute (to honour 
Carlos Finlay) in 1991.  
 1990, the Cuban Centre for Neuroscience: for the diagnosis and treatment of brain diseases.  
 1992, the Centre of Biopreparados: to produce Cuban biologicals.  
 1994, Centre of Molecular Immunology.  
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Along with the pace of these state investments, the astonishing fact is that they took place in the 
midst of Cuba’s most acute economic crisis: the Special Period which began in autumn 1990, as the 
case of Cuba’s Centre for Molecular Immunology shows.  
 
Oncology meets biotechnology  
In the 1980s, biotechnology and oncology began to converge globally. In Cuba’s National Institute of 
Oncology and Radiobiology (which emerged from the Hospital of Oncology that Guevara had once 
commandeered), Lage was among a group of young scientists working on an experimental project 
into the role of immunology to fight cancer. In the early 1980s, INOR developed and trialled the first 
Cuban monoclonal antibodies (MABs) – clones of single antibody cells - with multiple medical uses. 
By the late 1980s, MABs were used for detecting malignant tumours and preventing organ rejection 
in Cuban transplant patients.56 After a visit to INOR in 1989, Fidel Castro recommended expanding 
the institution, integrating it into the Scientific Pole, and providing it with industrial production 
capacity and authorisation to export. Construction began in 1991. In December 1991, when the USSR 
collapsed, only the prefabricated columns of the new Centre of Molecular Immunology (CIM) had 
been laid. Nonetheless, Fidel would not allow the project to be halted. Lage describes this as: ‘a very 
audacious decision, when the country had no financial resources to say “this centre has to be 
completed”. It was a Fidel’s decision, a kind of offensive defence.’57 The fact that the sector was 
entirely state-owned and controlled made that decision possible, and necessary, if CIM was to 
continue. 
 
The Special Period - biotechnology exempt!  
The collapse of the USSR and Eastern European socialism had a traumatic economic impact on Cuba. 
From having 85% of its trade conducted under planned agreements with socialist countries 
(unimpeded by the US blockade), Cuba was suddenly dependent on an international capitalist market 
dominated by the US, the country pursuing a merciless blockade on the island. One-third of world 
pharmaceutical production took place in the US. From where could Cuba get medical equipment and 
medicines? 
 
In 1993, as Cuban socialism tottered on the edge of an abyss after GDP plummeted 35% in two years, 
Elsewhere there were drastic cuts, things fell apart, production and transport halted, belts tightened 
14 
 
and scarcity appeared in almost every sector and space. In this context, the inherently high-risk 
nascent biotechnology sector was selected as one of three strategic economic sectors for investment, 
along with tourism and food production.  
 
Between 1990 and 1996, another US $1 billion (1.5% of Cuba’s GNP) was invested into the Scientific 
Pole. It functioned as an incubator of medical science enterprises which were protected directly by 
the President’s office during the Special Period. When the institutions began to export, that money 
was reinvested into them; a ‘closed economic cycle’ was created. Thus it was in the most difficult 
economic period that Cuban biotechnology flourished. The motivation was domestic public health 
benefits, explains Lage. ‘And because of the US blockade. We could not afford expensive drugs, 
sometimes we could not get them even if we had all the money in the world, because they would 
not sell them’.58 Elsewhere in Latin America, neoliberal structural adjustment programmes saw public 
health provision privatised and rolled back in the 1990s, but the Cuban government held steadfast 
to its social-welfare orientated centrally-planned economy.59   
 
Gradually the dust covering the country’s pharmacy shelves was replaced by Cuban manufactured 
‘biosimilars’ - copies of traditional and biotechnological medicines, as Cuba’s medical science sector 
was channelled to meet this need. Copying biotech products involves high-level science; to synthesise 
genes and introduce them into cells to clone them. Cuba’s interferon, erythropoietin, the vaccine 
against Hepatitis B have all been ‘copy products’. Homeopathic alternatives also claimed shelf space. 
The need for cheap generic drugs was international, so Cuba increased its pharmaceutical exports. 
By the mid-1990s, they were earning $100 million a year.  
 
Biotechnology with Cuban characteristics 
The president of a multinational pharmaceutical company once told Lage that he was bound by his 
share-holders’ interests. The director of CIM asked how many shareholders his company had. The 
answer was 300,000. Lage replied, ‘well, I have 11 million. Our shareholders are all 11 million 
Cubans!’60 Founded solely through state investment, with financing guaranteed through the state 
budget, the Cuban biopharma sector is state owned, with no private interests or speculative 
investments. Profit is not sought domestically, because the sector is completely integrated into the 
state-funded public health system. National health needs are prioritised. Medicines that Cuba cannot 
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afford, or cannot get access to because of the US blockade have to be produced domestically. Today, 
517 of the 800 or so medicines consumed in Cuba are produced domestically, close to 70%.  
 
Cooperation prevails over competition as research and innovations are shared between institutions. 
Teams of scientists are established to take a project through from basic science, to product-oriented 
research, to manufacturing and marketing; activities that are carried out by different businesses in 
most countries. Dr Kelvin Lee is the Chair of Immunology in Roswell Park Comprehensive Cancer 
Centre in Buffalo, New York, and is currently leading clinical trials on CIM’s CIMAVax-EFG, a 
therapeutic cancer vaccine for patients with advanced lung cancer.61 He highlights these ‘striking’ 
and ‘unique’ characteristics of the Cuban biotech sector: ‘They start with identifying a need, then 
figure out the science to develop that in the lab, manufacture their agent, test it in the Cuban medical 
system and then commercialise it and sell it overseas. Their system is particularly nimble in that 
ability.’ The disadvantage the Cubans face, he adds, is that they can’t pursue thousands of good ideas 
and write off those which don’t work as sunk costs. ‘They don’t have the resources to do that’.62 Their 
access to capital is extremely limited. So what, then, have been fruits of this distinctive Cuban 
system?  
 
The Cuban cure  
In 2015, the World Health Organisation announced that Cuba was first in the world to eliminate 
mother-to-child HIV transmission. Cuba has prevented an AIDS epidemic with domestically produced 
antiretroviral medicine that halts patient transmission, as if it were a vaccine. Cuba’s mortality curve 
for AIDS continues to fall. The universal use of the CIGB’s hepatitis B vaccine on new-borns means 
Cuba should be among the first countries free from Hepatitis B. This is one of the eight vaccines (out 
of 11 vaccines for 13 diseases) administered to Cuban children which are produced in Science City. 
Within ten years, 100 million doses of Cuba’s Hep B vaccine were used around the world.  
 
By 2017, CIGB employed 1,600 people and sold 21 products internationally. CIGB’s portfolio of 
innovations with major public health implications includes Heberprot-P for diabetic foot ulcers, 
affecting some 422 million people worldwide, which reduces the need for amputations by 71%.63  In 
ten years, 71,000 patients in Cuba have been treated with Heberprot-P plus 130,000 people in 26 
other countries. The CIGB also has products for the agricultural and food production sectors.  
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Cuba was second in the Americas to achieve a complete congenital hypothyroidism screening 
programme, after Canada and before the United States. Cuba’s Immunoassay Centre developed its 
own Ultramicroanalytic System (SUMA) equipment for prenatal diagnosis for congenital anomalies. 
Among other things, nearly 4 million babies have been tested for congenital hypothyroidism, which 
effects the production of thyroxine, a hormone needed for normal growth and development.64 
Treatment is easy and cheap. ‘Since this system was introduced some children who would have had 
problems with mental development are in the universities’ (Lage). In 2017, the Immunoassay Centre 
had 418 workers producing 57 million tests per year for 19 different conditions, including Hepatitis B 
and C, dengue fever, cystic fibrosis, Chagas disease, leprosy and HIV.  
 
Cuba’s Centre for Neuroscience is developing cognitive and biomarker tests for early screening of 
Alzheimer’s disease. They have developed a hearing aid for children that costs just (US) $2, a fraction 
of the cost in the US and Europe, made to individual specification using a 3D printer.65  
 
Cuban professionals have received ten gold medals from the World Intellectual Property 
Organisation (WIPO) over 26 years. The first was in 1989 for the Meningitis B vaccine; another was 
for the Haemophilus influenza type b (Hib) vaccine,66 the result of a collaboration with the University 
of Ottawa; also for Heberprot-P; and Itolizumab for treating psoriasis.67 By summer 2017, the Cuban 
biotech sector boasted 182 inventions with 543 patents granted in Cuba, 1816 patents abroad and 
2336 patent applications.68 Its products were marketed in 49 countries and it had partnerships with 
nine countries in the global south. Cuba’s pharmaceutical industry has the capacity for large-scale 
production of Cuban and generic drugs for export cheaply to developing countries.  
 
CIM’s focus is on biotechnology of mammalian cells; monoclonal antibodies and cancer vaccines. 
Cancer is the biggest cause of death for under 65 year olds in Cuba, and second only to heart disease 
for over 65s. By summer 2017 CIM had 1,100 employees, 4 manufacturing facilities, 25 products in 
the pipeline, 6 registered products, exported to 30 countries, had 5 joint-venture companies abroad, 
45 patented inventions, and 750 patents abroad. Over 90,000 Cubans had been treated by CIM 
products. Among CIM’s most exciting innovations is CIMAvax: EFG, the lung cancer immunotherapy.   
 
The term ‘cancer’ refers to a group of diseases involving abnormal cell growth with the potential to 
invade or spread to other parts of the body. Epidermal growth factor, or EFG, is a cellular protein that 
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stimulates cell growth by binding to cells via epidermal growth factor receptors (EGFRs) on the cell 
surface. Back in 1984, Lage and the scientists at INOR were first in the world to describe the role of 
EGFRs in breast cancer: EGFRs were over-expressed in 60% of human breast tumours. They 
discovered that EGF was rapidly distributed, reached tumour cells and recognised specific cell 
membrane receptors. Lage reported: ‘These results suggest that high doses of EGF could eventually 
be used for inhibition of the cell proliferation in some tumours.’ Up until that point, EFG had been 
seen as part of the cancer problem; it nourishes tumours yet is natural to the body so it does not 
trigger the immune system. The Cubans were proposing to use human EFG as part of the solution: as 
an active agent that could be used to interfere with the normal, cancer-producing binding of EFG to 
its receptor – the EFGR.69 
 
It is because the immune system struggles to recognise cancer as foreign to the body, that 
immunology therapy to combat cancer had proven so difficult. CIM wanted to use EFG to ‘train’ the 
body to respond to EFG and so produce cancer-specific antibodies. No other cancer researchers had 
managed it. This therapy would require one or two doses of a vaccine which would be cheap to 
develop and could be delivered through primary health care. This suits for the Cuban medical system. 
However, because it does not involve a lengthy course of expensive therapy in high-tech institutions, 
it is arguably antithetical to the profit-motivated interests of the global biopharma corporations. 
CIMAVax built on the Cuban therapeutic expertise of the vaccinologists at the Finlay Institute 
(Meningitis B) and the CIGB’s work on recombinant protein from Neisseria meningitides bacteria P64 
K. By using P64 K as a carrier protein with which to introduce EFG into patient’s body, the researchers 
at CIM broke the body’s tolerance to its own EFG.70 The results are a vaccine that helps the body to 
help itself. Dr Kelvin Lee points out that the Cubans ‘designed their lung cancer vaccine to actually be 
useful in things like colon cancer, head and neck cancer, breast cancer, pancreatic cancer. It has broad 
applicability.’71 The Roswell Park/CIM joint venture, Innovative Immunotherapy Alliance, will be 
investigating some of these additional potentials. 
 
These biotech achievements are accompanied by demographic ones. Most employees in Cuba’s 
medical science centres are the children and grandchildren of workers and peasants, beneficiaries of 
Cuba’s free education system. Today, 66% of Cuba’s science and technology personnel are women.72 
The inordinate additional burdens imposed on the sector by the unrelenting and extensive US 
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blockade has undoubtedly impoverished Cuba, denying the island access to resources, markets and 
knowledge transfers. But it has also fostered resilience and creativity in Cuban scientists.73  
 
BioCubaFarma  
In 2012, BioCubaFarma was created as a kind of ‘holding company’ for the pharmaceutical and 
biotechnology sectors. It integrated 38 companies, 60 manufacturing facilities and 22,000 workers, 
almost one-third of them scientists and engineers. By 2017, BioCubaFarma was exporting to nearly 
50 countries with over 2,000 patents granted abroad. This reorganisation of Cuban medical science 
is integral to the broader restructuring of the Cuban economy under the ‘guidelines for updating the 
economic and social model’. The economic reforms, which were initially introduced in 2011, confirm 
a key role for the biopharma sector in the national development plan. But only 1% of the nearly 3,000 
Cuban state enterprises export innovative scientific products. How can this sector expand without 
the kind of speculative private investment and profit-motivated competition which characterises the 
capitalist biotech industry?  
 
Lage conceptualises ‘high-tech socialist state enterprises’ in Cuba, requiring a distinct regulatory 
framework from the ‘budgeted sector’ (health, education and other social provisions funded entirely 
by state budget) and the state enterprise sector (state owned and expected to contribute towards 
the national coffers).74 There is commitment to maintain biotechnology institutions under state 
control, with state investment for scientific research, with the sector increasingly contributing to 
economic growth through the export of high value-added products in a context of a state-monopoly 
over foreign trade. This requires strengthening of the integration between science and production, 
research institutions and universities and the promotion of the close-cycle of production.  
 
Cuban biotech exports  
Several global biopharma corporations have demonstrated interest in Cuban biotech products, but 
the US blockade, and the threat of receiving a huge fine, has largely proven an effective disincentive. 
Cuban collaborations with the global south have been more successful, in terms of exports and joint 
ventures. The knowledge economy in small countries has to be developed on the basis of exports, 
because domestic demand is insufficient. Between 2008 and 2013, Cuban biotech sales earned $2.5 
billion USD.75 By 2017, this had risen to $500,000 annually. The low cost of Cuba’s biopharma exports 
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is an incentive for governments in the global south to pursue deals. CIMAvax costs $1 per shot to 
manufacture, much cheaper than alternative lung cancer treatments.  
 
The sector has also established joint ventures with foreign (state) companies. By 2017, the Cuban 
biotech sector had joint ventures operating in Brazil, China, Venezuela, Algeria, South Africa, 
Vietnam, India, Thailand and Iran. CIM alone has three joint ventures in China, manufacturing, 
variously, monoclonal antibodies and therapeutic cancer vaccines, recombinant proteins and biotech 
products for agriculture. Lage boasts that China - a country with 1 billion inhabitants, which produces 
aeroplanes and heavy industry - made its first monoclonal antibodies with Cuban technology.76 The 
CIGB also has two joint ventures with China. A Cuba-China workgroup oversees the collaboration 
between the two countries. CIM also has two marketing joint-ventures, in Spain, for therapeutic 
cancer vaccines, and in Singapore for monoclonal antibodies. Another mixed enterprise is being set 
up in Russia.  
 
The first Cuban patents are expiring, and the race is on to produce new innovative products. Globally, 
the average annual costs of research and development for new drugs is increasing. Between the 
1980s and 2006 it increased 7.4%.77 A 2014 report calculated the cost of developing a prescription 
drug that gains market approval at $2.6 billion, a 145% increase over their previous estimate in 
2003.78 Cuba is now bidding for substantial foreign investment in its biopharma industry.79 However, 
there is no intention to relinquish state ownership of the sector, or to privatise it in any other form. 
The Cuban government does not want foreigners to fund innovations, thus claiming a stake in them. 
It wants investment in creating its industrial production capacity and it needs partners to help insert 
Cuban products into the global market, subverting the US blockade and increasing export earnings. 
 
In the process of unravelling the US-Cuban rapprochement, on 8 November 2017, US President 
Trump’s administration published a list of Cuban entities and sub-entities which US citizens and 
businesses are prohibited from engaging. This placed the breaks on new cooperation with the US, 
and because of the extraterritorial character of the blockade, with its European allies too. However, 
the insertion of a ‘grandfather’ clause meant that collaborations licensed under Obama, like the one 
between CIM and Roswell Park, can continue. There are ways and means around these regulations, 
even for US businesses, if they are determined. And given Cuban medical science breakthroughs on 
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some key global health issues, such as cancer, HIV and AIDs, hepatitis and infectious diseases, it is 
likely they will find increasing incentives to do so.   
 
Conclusion 
With increasing frequency, Cuba’s biotech breakthroughs are making global headlines. Cuba’s 
biotechnology success can be understood in the context of the post-1959 commitment to high-
standard, universal free public health and education, which created a ‘critical mass’ of medical 
scientists. It also reflects the political will of the country’s leadership, particularly Fidel Castro, to 
develop science and technology as a means to socioeconomic development. It builds on a long history 
of infectious disease research and vaccinations. The US blockade also imposed the need to meet 
domestic demand for medical products with domestic production. The question of state control in a 
planned economy is also key. The flow between universities, research centres, medical science 
enterprises and the public health system is far more fluid than elsewhere, precisely because there is 
no proprietor-based conflicts of interest. The state controls production and distribution, equally of 
scientists and researchers as of medical products and innovations.  
 
Research demonstrating the ‘inseparability of the biotechnology industry and the state…in the US 
and elsewhere’,80 highlights that the curious case of Cuba’s biotech revolution is about far more than 
government support for the sector. The US government supports the biopharma sector with public-
research funding, legislation and patenting laws. It has also fostered the venture capital sector, on 
which biotech firms principally rely, through favourable monetary and fiscal policies and regulations. 
In the US, the danger is that the private interests of venture capitalists obstruct medical science 
innovations which would bring public health benefits globally. In Cuba, the challenges are accessing 
capital and navigating the US blockade which obstructs access to foreign biopharma partners, export 
markets, and patents and resources from around the world.  
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